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Abstract
Background: One well-accepted strategy for optimising outcomes in mammographic breast cancer screening is to
improve communication with women about screening. It is not always clear, however, what it is that communication
should be expected to achieve, and why or how this is so. We investigated Australian experts’ opinions on breast
screening communication. Our research questions were: 1 What are the views of Australian experts about
communicating with consumers on breast screening? 2 How do experts reason about this topic?
Methods: We used a qualitative methodology, interviewing 33 breast screening experts across Australia with
recognisable influence in the Australian mammographic breast cancer screening setting. We used purposive and
theoretical sampling to identify experts from different professional roles (including clinicians, program managers,
policy makers, advocates and researchers) with a range of opinions about communication in breast screening.
Results: Experts discussed the topic of communication with consumers by focusing on two main questions: how
strongly to guide consumers’ breast cancer screening choices, and what to communicate about overdiagnosis. Each
expert adopted one of three approaches to consumer communication depending on their views about these topics.
We labelled these approaches: Be screened; Be screened and here’s why; Screening is available please consider
whether it’s right for you. There was a similar level of support for all three approaches. Experts’ reasoning was
grounded in how they conceived of and prioritised their underlying values including: delivering benefits, avoiding
harms, delivering more benefits than harms, respecting autonomy and transparency.
Conclusions: There is disagreement between experts regarding communication with breast screening consumers.
Our study provides some insights into this persisting lack of consensus, highlighting the different meanings that
experts give to values, and different ways that values are prioritised. We suggest that explicit discussion about
ethical values might help to focus thinking, clarify concepts and promote consensus in policy around communication
with consumers. More specifically, we suggest that decision-makers who are considering policy on screening
communication should begin with identifying and agreeing on the specific values to be prioritised and use this to
guide them in establishing what the communication aims will be and which communication strategy will achieve
those aims.
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Background
Mammographic breast screening opportunities and pro-
grams have been introduced in many high-income
countries over the past three decades [1–3], with the
expectation of achieving significant population breast
cancer mortality reduction. This outcome was suggested
by evidence from early randomised control trials (RCTs)
and cohort studies [1, 2] and later backed up by further
studies and multi-study reviews [4, 5]. In Australia the
government provides free biennial screening mammog-
raphy for all women over 40 years of age through its na-
tional program BreastScreen Australia [6]. The government
actively encourages the regular participation of women
aged 50–74 years, with promotional communications fo-
cusing on this target age range [7]. An important focus of
breast screening research has been how to communicate
effectively with women in order to achieve high screening
participation rates and realise the mortality benefits de-
scribed in the literature [8].
At the same time there has been growing interest in
encouraging and supporting members of the public to
be more informed about health matters, including
screening, and more engaged in decisions about their
own healthcare [9–13]. This is partly underpinned by a
desire to respect the autonomy of patients and health-
care consumers [14–16] and partly for reasons such as
engendering greater public satisfaction, more efficient
use of healthcare services and possibly even better health
outcomes for individuals and communities [17–19].
More recently, uncertainties about both benefits and
harms of breast screening have emerged. The benefits
may be less than first anticipated from the early studies.
Meta-analyses of what is by now a substantial body of
RCT evidence on mammographic breast screening pro-
vide different estimates of benefit, depending on which
of the RCTs are considered to be of sufficiently high
quality to include in the review [20, 21]. There are also
suggestions that the RCT evidence may be out of date,
with recent improvements in breast cancer treatment to-
gether with increased awareness about prompt symp-
tomatic presentation leaving less room for screening to
have a beneficial effect [22, 23]. At the same time, a
growing body of research is contributing to concern
about harms associated with breast screening, including
cumulative false positive tests [22] and overdiagnosis
(the diagnosis of non-progressive or slowly progressive
breast cancer through screening, a diagnosis that does
not produce a net benefit for the woman diagnosed)
[24–27]. The amount and significance of overdiagnosis
harm is particularly contentious [23]. There is concern
about whether or not hearing about these uncertainties
and harms will deter women from screening, and in-
deed recent RCT evidence does suggest that women
who are more informed about overdiagnosis express a
lower intention to screen [28]. A perceived tension
has thus arisen between the aim of achieving high
breast screening participation rates and the aim of
enabling women to make informed choices about
screening, with debate about whether communication
with consumers should focus on maximising partici-
pation or on communicating to support citizen’s
knowledge and autonomy [29].
Official government policy endorses shared decision
making to achieve informed choice in healthcare gener-
ally and in screening more specifically [30, 31]. Many
claim that informed choice is particularly pertinent to
screening because it actively targets healthy people ra-
ther than sick people who are seeking help for symp-
toms. Others highlight the importance of informed
choice in those screening programs for which evidence
about outcomes is insufficient or controversial, or where
benefits and harms are finely balanced such that individ-
ual values become relatively more important in guiding
decisions about being screened [32, 33]. There have been
concerns that government directives to facilitate in-
formed choice are not being adequately followed within
breast screening [29, 34–36], with international criticism
of breast screening information pamphlets on the
grounds that they withhold important information about
possible harms of breast screening [37–40], and sugges-
tions that consumers should be explicitly encouraged to
make their own choice whether or not to attend screen-
ing [36, 41, 42]. Not all authors prioritise the target of
achieving informed consumer choice in cancer screen-
ing. Some prefer to focus on achieving adequate uptake
in order to realise screening benefits [43]. Others have
concerns about the process or reasoning behind such a
target. For example, some writers suggest that it may be
unreasonable to expect even fully informed citizens to
take on what they depict as the burdensome task of
decision making for cancer screening: weighing up
uncertain benefits and harms, about which experts dis-
agree [44]. Others contend that requiring or encouraging
informed citizen decision making about cancer screening
may be unecessary since, arguably, justification for it
may rely on an inapporpriately narrow version of auton-
omy [45]. According to this view, a respectful approach
should accommodate citizens who wish to rely on others
to guide or choose for them. Finally, some argue that
providing citizens with enough information to make
fully informed screening choices may be prohibitively
time consuming [46].
It is well-recognised that there are differences of opin-
ion amongst clinicians regarding the involvement of
patients in decision making for clinical care [47] and it
is known that there are differences in how frequently or
enthusiastically primary care practitioners discuss mam-
mographic breast screening with their patients [48–50].
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The ongoing discussions in the academic literature about
the aims and content of breast screening communication
suggests there is also likely to be diversity of expert opin-
ion about policies for consumer decision making in rela-
tion to breast screening [29]. We could find no empirical
work that examined this topic and to fill this gap we inves-
tigated the opinions and priorities of influential Australian
experts with respect to breast screening communication
with consumers. Our research questions were:
 What are the views of Australian experts about what
and how we should communicate with consumers
about breast screening?
 How do experts reason about this topic and how
does this explain the positions they take?
Methods
Methodology
Our study was part of a larger project exploring the social
and ethical issues around cancer screening in Australia
[51]. Data collection from experts in breast screening was
undertaken as a sub-study in the project, and this paper
reports on one component of the sub-study. Other com-
ponents of the sub-study involving analysis of different
aspects of the data set have been written up separately
[52]. We used an empirical, qualitative methodology. The
emerging research field of “empirical bioethics” uses em-
pirical research methods alongside traditional theoretical
ethics in the context of healthcare and other biological
sciences. Empirical methods are used to study and de-
scribe an ethical issue; theory is used to varying degrees by
different researchers to shape the empirical study and
inform interpretation and discussion of findings. We situ-
ate ourselves close to the style of Frith [53], who combines
empirical and theoretical ethics in a symbiotic relation-
ship, arguing that each can and should, inform eachother
[54]. We used sampling, data collection and analysis strat-
egies that were best suited to the particular circumstances
and aims of our project, and enabled us to conduct our
study with internal coherence [55–58].
Participants and sampling
We sought to include influential breast screening ex-
perts from within Australia as participants. We defined
influential experts as people with experience of working
in a field directly related to breast screening in Australia
and who had influence through one or more of: senior
service delivery; academic or lay publication; member-
ship of government or professional advisory committee;
senior position in non-government breast screening or-
ganisation or consumer group. We sought to maximise
the diversity of perspectives amongst our participants by
deliberately seeking experts known to have publically
expressed divergent opinions about breast screening
(loosely categorised by us as being “supportive”, “mostly
supportive” or “critical”) and experts from a range of
professional roles across Australia including clinical
practice, research, program administration, advisory staff
and consumer advocacy.
We identified potential participants by reading local aca-
demic and lay literature; scanning personnel lists on web-
sites of government and non-government organisations;
and following up on suggestions from previously inter-
viewed experts and from colleagues involved in cancer
screening research. We approached 46 experts via email
and interviewed 33 (17 males, 16 females). The remainder
were unavailable (1), unwilling (3) or did not respond (9).
We had a particularly low response rate from volunteers
in consumer advocacy roles, which may have been at least
partly due to a higher turnover of people in these posi-
tions than in other professional roles – that is, they may
no longer have been acting in a senior advocacy capacity
when our email was sent.
We performed our analysis in parallel with data collec-
tion, and used the information in the early interviews to
direct further sampling, aiming to capture and explore
the range of different ideas about this topic. We contin-
ued sampling until we were satisfied that we had suffi-
cient diversity of opinions and roles [58] (Table 1) and
until we were no longer hearing any new information.
(thematic saturation) [54, 57].
Data collection
LP conducted semi structured interviews between October
2012 and October 2013. The interviews lasted an average
of 66 min (range 39–105 min) and were conducted in the
expert’s or in LP’s workplace, or by telephone if unavailable
to meet in person. Making use of telephone inter-
views enabled us to speak with experts from disparate
locations around the country and we found that tele-
phone interviews were similar in quality and length
to face-to-face interviews [59].
LP discussed her interest in the topic with experts,
explaining that she was a medical practitioner with clin-
ical experience in breast screening, currently undertak-
ing doctoral studies in cancer-screening ethics. She
informed participants that the purpose of the interviews
was to glean the range of opinions amongst Australian
experts about breast screening. They were asked about
their general attitudes to the current program, their sug-
gestions and hopes for the future of the program, and
their opinions on communicating with consumers (Add-
itional file 1). The interviews were digitally recorded,
professionally transcribed and any identifying informa-
tion (such as person or place names) that was articulated
during the discussion was removed from the transcripts
before analysis began.
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Analysis
Analysis involved iterative reading, coding and categor-
isation of interview data. We sought to identify and
understand the range of attitudes and underlying values
that experts expressed around the topic of consumer
communication. Repeated reading was undertaken in
conjunction with the generation of a set of codes that
captured attitudes and values, and the development of
more abstract categories, that evolved as data collection
and analysis progressed. LP wrote case-based memos
throughout the project and shared these and provisional
analysis with the other authors [58]. All authors contrib-
uted to ongoing analysis, involving comparison between
codes and data, revision of findings and development of
concepts presented in this paper.
Ethics approval
Ethics approval was granted from the Cancer Institute
NSW Population & Health Services Research Ethics
Committee [HREC/12/CIPHS/46] and the University of
Sydney Human Research Ethics Committee [#15245].
All participants gave written or verbal informed consent
to their involvement in the study (those who were inter-
viewed face to face gave verbal consent; those who were
interviewed via telephone gave verbal consent). This
research complies with current Australian laws and
guidelines.
Results
Expert opinions on communicating with consumers
Experts spoke in detail about communicating with con-
sumers regarding breast screening. Their comments
focused on two issues: 1) the degree of guidance for con-
sumers, and 2) the extent of information provided to
consumers about overdiagnosis. Table 2 shows how ex-
perts’ views on communication could be divided into
three approaches according to the interaction between
these two issues (guidance and overdiagnosis informa-
tion). The first approach, which we have named “Be
screened”, combined guiding consumers towards screen-
ing with limited information on overdiagnosis. The sec-
ond approach, “Be screened and here’s why”, combined
guiding consumers towards screening with full con-
sumer information. The third approach, “Screening is
available, please consider whether it’s right for you”
combined no guidance about screening with full con-
sumer information. We found a similar level of expert
support for each of the three approaches. Logically there
could potentially have been a fourth approach (no guid-
ance and limited information – see Table 2) but there
were no experts who advocated for this position. All
experts were in favour of either guidance or full infor-
mation or both; there were no experts who would rec-
ommend no guidance and no means for consumers to
make an informed choice of their own.
Overall more experts preferred guiding women to be
screened, and overall more experts preferred that full
information be provided. Examining Table 2, and recalling
that there were approximately the same number of experts
in each cell, reveals why. Two out of three approaches
(“Be screened” and “Be screened and here’s why”) sup-
ported guidance to screen. Two out of three approaches
(“Be screened and here’s why” and “Screening is available”)
supported the provision of full information on overdiag-
nosis. Thus providing guidance, and providing full infor-
mation, were preferred to the alternatives.
Expert descriptions of what it means to guide consumers
to be screened, or not
The detail in Table 2 describes experts’ ideas of what it
means to guide consumers to be screened, or not. The
majority argued that consumer communication should
include guidance towards screening. They endorsed the
existing strategy whereby the screening provider is the
main source of guidance. They also approved of current
participation targets for screening units, suggesting they
Table 1 Characteristics of experts
Participants 33 (Experts who were invited but did
not-participate 13)
Professional rolea Cliniciansb15 (3) Oncologists 3 (1)
Surgeons 4 (0)
Breast physicians 1 (2)
Radiologists 2 (0)
Radiation oncologists 2 (0)
Pathologists 3 (0)
Other 0 (1)
Non-clinical
researchers 14 (3)
Epidemiologists/
biostatisticians 9 (1)
Other 5 (1)
Administrators/
managers 6 (2)
6 (2)
Advocacy leaders
6 (7)
Consumers working in
advocacy 3 (6)
Clinicians/researchers
working in advocacy 3 (1)
Public stance on
breast screeningc
Supportive 16 (9)
Mostly supportived 3 (1)
Critical 6 (0)
Unknown to researchers 8 (3)
anote that some experts held more than one professional role, for this reason
the numbers attached to specific professional roles do not neatly add up to
n = 33 (participants) or n = 13 (experts invited but not participating)
bmost clinicians engaged in research to a greater or lesser extent
cWe loosely categorised potential interviewees as being “supportive”, “mostly
supportive” or “critical” about breast screening based on publicly
available commentary
dbroadly supportive of breast screening but with selected concerns about one
or more elements of the program
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were a useful tool for developing and maintaining a suc-
cessful guidance strategy. Several experts advocated ex-
tending and enhancing consumer guidance by providing
greater marketing support to local screening units, along
with education and reminders for primary care practi-
tioners to take a more active role in promoting breast
screening.
A smaller number of experts recommended against
guiding women to participate in screening (Table 2).
These experts suggested that consumers be educated
about the availability of screening, encouraged to under-
stand benefits and harms, then asked to carefully con-
sider whether or not the program was right for them.
They recommended that communications with con-
sumers be written by an independent body, suggesting
that providers were likely to view and/or present screening
in a favourable light. These experts were in favour of
replacing participation targets with targets around infor-
mation provision or public understanding of screening.
They opposed personalised letters of invitation, suggesting
Table 2 Experts’ preferences regarding guidance and information when communicating with women about breast cancer
screening
Possible elements in a guidance vs no guidance approach (collated from experts’
comments)
Experts who preferred guiding women
to screen advocated for the following:
Experts who preferred not to guide
women’s screening choices advocated
for the following:
● Provider-to-consumer guidance to
screen via public promotional
advertising & personalised letters of
invitation to women from the screening
program
● An independent body to provide
information to women about
screening options & encourage
them to make a thoughtful choice
about participation
● Marketing support & participation
targets for local breast screening units
to ensure guidance is effective at
maintaining high participation
● Online decision aid tools available
to consumers
● No personalised invitations
● Targets for consumer understanding
rather than participation
● Educational support & electronic
reminders to enhance GP-to-consumer
guidance to screen
● Educational support to enhance GP
assistance for women to make an
informed screening choice
● Directed advice available from GP
upon request
Possible characteristics of a
limited vs full information
approach (collated from
experts’ comments)
Experts who preferred limiting the
overdiagnosis information presented
to women advocated for the
following content in consumer
communications:
“Be screened”a n/a
● Information that breast screening
saves lives
● Information that a recall does not
necessarily mean you have cancer
● Brief mention that overdiagnosis is
a possibility and that it is unlikely
● Advising that further information is
available to women upon request
Experts who preferred providing full
information to women advocated
for the following content in
consumer communications:
“Be screened and here’s why”a “Screening is available, please consider
whether it is right for you”a
● Detailed information about
mortality benefit, false positives &
overdiagnosis associated with
breast screening
● Numerical/pictorial comparison of
chances of deriving benefit &
being overdiagnosed
athere was roughly an equal number of experts supporting each of the three named approaches
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that these carried the weight of government support and
would therefore be seen by women as persuasive, even
coercive. A couple of experts explicitly suggested that
women should be given assistance with decision making,
discussing strategies such as online decision making tools
and primary care practitioner support in understanding
the evidence and making choices in accordance with con-
sumers’ personal values. They suggested that guidance
about screening could be made available for those who
wanted it.
Expert descriptions of what it means to inform consumers
about overdiagnosis, or not
Experts described two approaches to information about
overdiagnosis (Table 2). The majority of experts thought
that information about overdiagnosis should be limited.
These experts thought consumer communications should
impart simple, uncomplicated information about screen-
ing benefit, with limited detail on possible downsides.
They suggested overdiagnosis information should be pre-
sented briefly along the lines of, “some of the things that
we are going to be treating you for may not progress.”
(Expert #33, clinician and provider) These experts pro-
posed that further information could be made available
for those who wanted it. Contrary to this position, a
smaller group of experts advocated full information about
both benefits and harms of breast screening. They particu-
larly wanted consumers to be provided with understandable
data about overdiagnosis, including readily comparable
information on chances of mortality benefit versus
overdiagnosis.
Experts’ reasoning about their preferred communication
approach
Experts gave a variety of reasons to explain their positions
on communicating with consumers. Table 3 presents the
range of reasons for experts’ preferred approaches to breast
screening communications. Further data, including quota-
tions from experts that encapsulates the range of reasoning
about communications, is included in Additional file 2. The
major concerns of experts are discussed below.
Experts’ reasoning about guidance to attend screening
Experts who preferred guidance for consumers were par-
ticularly concerned to maximise screening participation
rates in order to deliver breast cancer related benefits to
individuals and populations. Many also reasoned that
guidance was important because benefits of screening
outweighed harms. Some experts added to this by assert-
ing that overdiagnosis was not a harm, rather that the
diagnosis of small cancers was exactly what the screen-
ing program was intended to do in order to reduce
breast cancer mortality and morbidity. Experts also
argued beyond the breast screening context, suggesting
that providing advice and guidance on health matters
were important public health responsibilities.
Experts who advocated against guidance were worried
about overdiagnosis harms and were enthusiastic about
enabling individual consumers to make their own deci-
sions about health. They suggested that independent
consumer decision making was particularly important in
breast screening because of the close balance between
benefits and harms, and what experts saw as the individ-
ual nature of the benefits. These experts suggested that,
unlike some other public health programs, there was no
community benefit associated with individual participa-
tion in breast screening: “there is a community benefit
from immunisation, but there’s no such community bene-
fit from screening. Like, the benefit is to the individual,”
(expert #8, researcher) because, “if I choose not to go, the
only person that’s being harmed by my choice is me. I’m
not giving the person next door to me breast cancer.”
(Expert #27, researcher). They also expressed concerns
that breast screening enthusiasts might not necessarily
act in the best interests of individual consumers. For ex-
ample, these experts suggested that governments might
be driven by the promise of political gain from address-
ing women’s health, and that providers and clinicians
may have vested interests in their own employment
security and remuneration.
Both groups referred to evidence-based decision mak-
ing to justify their positions about guidance. Those pre-
ferring guidance suggested that individual consumers
would be unable to understand the complex evidence
and should therefore be provided with advice from ex-
perts about where the balance of benefits and harms lies.
Those against guidance suggested that consumers, rather
than experts, were better placed to use the evidence
appropriately, since experts tended to ignore the harms
and focus on the benefits. One expert advocated against
guidance on the basis that, as they saw it, the evidence
showed breast screening was likely to deliver more
population harms than benefits. They believed that ad-
vising against screening was politically unacceptable, so
removing guidance to screen was the next best option.
Experts’ reasoning about providing information on
overdiagnosis
Experts who expressed a preference for limiting infor-
mation to consumers were mainly concerned about the
potential impact of discussing overdiagnosis. They sug-
gested that detailed information about overdiagnosis
may result in consumers becoming confused or scared,
decreasing the likelihood that they would attend screen-
ing, and reducing their options for life-saving treatment.
As noted above and in Table 3, many of these experts
challenged the conception of overdiagnosis as a harm,
and used this to justify their support for both guidance
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and limited information. Importantly, these experts did
not see their preference for limiting overdiagnosis infor-
mation as being against informed decision making.
Many of these experts were consumer advocates, and
were strongly supportive of informed patient choice in
relation to breast cancer treatment. They explained their
apparently contradictory position on information about
screening versus treatment in two ways. Some stated
that the concept of overdiagnosis being a harm was
based on opinion, rather than fact and therefore did not
count as information. Other experts in this group sug-
gested that maximising screening uptake would enhance
patient choice (about life-saving treatments) because
early knowledge of breast cancer status was an import-
ant part of this.
Experts who preferred full information argued that
consumers should be informed about what they were
being asked to do. In particular these experts claimed
that full information on overdiagnosis was important for
its instrumental role in informed consumer decision
making.
Experts’ reasoning was grounded in underlying values
Table 4 shows how experts prioritise and conceptualise
values differently when discussing their communication
preferences. Some experts explicitly referred to values,
naming principles such as “delivering benefits”, “respect
for autonomy” and “avoiding harms”. Other experts were
more concrete in their discussion, but underlying values
could be readily discerned. Abstracting the experts’ rea-
soning in this way clarifies how values were used and
prioritised in association with particular communication
preferences. For example, experts who advocated for “Be
screened” prioritised the values of delivering benefits and
delivering more benefits than harms. Those who recom-
mended “Be screened and here’s why” added transparency
to this list. Experts who advocated for “Screening is avail-
able” prioritised avoiding harm, delivering more benefits
than harms and respect for autonomy.
Table 4 also shows that experts conceived of or applied
values differently, such that the same abstract value was
sometimes used to justify opposing communication pref-
erences. For example, although respect for autonomy
was prioritised by some more than others, all experts
were able to use this value to justify their preferences.
Those experts who preferred “Be screened” and “Be
screened and here’s why” saw the provision of guidance
to screen as being respectful of autonomy because it
would maximise consumer choices around breast cancer
treatment. Those who preferred the “Screening is avail-
able” approach suggested a no guidance agenda would
better respect autonomy because it facilitated informed
consumer decision making without expert or govern-
mental influences.
Table 3 Experts’ rationales for their stance on guidance and
information provision to women regarding breast screening
Guiding women towards breast screening
FOR
● Maximises screening participationa
● Saves livesa
● Women will have more treatment optionsa
● Overall, screening delivers more benefits than harms to the populationa
● Overdiagnosis is not a harm
● Providing guidance about good health is a government public health
responsibility
● You don’t want people to make decisions in public health, you just
want them to follow advice
● Expecting consumers to make their own informed choice is unfair
and unrealistic because the evidence is so complicated
● (Some) people want to be told what to do
AGAINST
● Individuals should be free to make their own decisionsa
● Personal autonomy is importanta
● Harm:benefit ratio is equivocal so screening should be an individual
choice, not a government-promoted activitya
● Screening affects only the individual concerned, so there is no
community-benefit argument to justify promotion of screening
● Others may not have the best interests of the individual consumer at
heart
● Consumers tend to be better than policy makers at remembering to
consider screening harms as well as benefits, so judgements about
screening should be left to consumers
● The harms of breast screening are greater than the benefits
Limiting consumer information on overdiagnosis
FOR
● Maximises screening participationa
● Calling overdiagnosis a “harm” is just one (mis)interpretation of the
facts
● Women don’t consider overdiagnosis a harm; main harms that
women care about are: pain, hassles of parking and making
appointments, radiation, breast damage, anxiety about recalls
● Population based information on overdiagnosis is not applicable to
individuals
● The real problem is not overdiagnosis but overtreatment
AGAINST
● People should know what they are signing up for when they
participate in screeninga
● Providing information enables informed decision makinga
● Informed decision making is particularly important for breast
screening because there are some downsidesa
● Providing full information is a professional responsibility
● (Some) women want full information
avery strongly/frequently expressed reasons
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Discussion
This study is, we believe, the first empirical exploration
of experts’ views on communicating with consumers
about breast screening. We found experts considered
the most important elements of this communication
were the degree of guidance and the amount of informa-
tion on overdiagnosis. These interacted to produce three
approaches to consumer communication: “Be screened”,
“Be screened and here’s why” or “Screening is available,
please consider whether it is right for you”. We expected
that experts would be conversant with academic and
public debates, and our study confirms that their views
on breast screening communications reflect ideas being
discussed in the literature [45]. The existence of contro-
versy about breast screening is widely recognised; our
results deliver both empirical confirmation and practical
detail to this broad recognition.
Our study explored the reasoning and motivation of
experts. Our analysis fits with and builds upon what
others have suggested about the aims of screening com-
munication. Many writers discuss what they see as the
competing goals of maximising participation versus re-
specting consumer autonomy by facilitating informed
choice about screening [29, 36, 60]. Our study explains
the reasoning of experts who aim to achieve one or both
goals. The detail in our study provides some insights
into why debates about communication persist. We
found experts disagree on what values to prioritise when
considering communication strategies and have different
conceptions of what it means to respect a particular
value, such as autonomy, in the context of breast screen-
ing. These results validate previous, more theoretical,
discussions about possible variations in use and concep-
tion of values in healthcare [16, 61, 62] and extend other
research looking at experts’ values in breast screening
generally [52]. It is not only the values of experts that
are important of course, but also the views and attitudes
of the public: our study sits alongside and complements
ongoing work into ascertaining public opinion about
topics such as consumer communication on cancer
screening [63, 64].
This study has implications for current debates about
the use of ethics frameworks in public health. The Four
Principles approach to medical ethics [65] is well recog-
nised as a useful tool for assisting decision making in
clinical practice and there is ongoing interest in promot-
ing ethical care alongside or as part of evidence based
medicine [66]. There is increasing recognition that the
particular aims, responsibilities and challenges of public
health as distinct from clinical medicine might be better
served with a specific set of principles or values [67, 68].
While there is ongoing discussion about what this might
look like, there seems to be broad support for some kind
of values-based public health ethics framework. Our
Table 4 Experts’ conceptualisation and prioritisation of values in three approaches to communication with consumers
Conception of values
underpinning the “Be
screened” approach
Conception of values
underpinning the “Be
screened and here’s why”
approach
Conception of values underpinning the
“Screening is available, please consider
whether it is right for you” approach
Values Delivering benefits Reduced breast cancer mortality
& reduced treatment related
morbiditya
Reduced breast cancer
mortality & reduced
treatment related morbiditya
Reduced all cause mortality and
morbidity
Avoiding harm Minimising pain, parking hassles,
radiation, anxiety about false
positives
Minimising pain, parking
hassles, radiation, anxiety
about false positives
Minimising overdiagnosis harmsa
Delivering more
benefits than harms
Experts informed by evidence
to assess population benefits
& harmsa
Experts informed by
evidence to assess
population benefits & harmsa
Consumers informed by evidence
and personal values to assess balance
of benefits & harms for themselvesa
Respect for autonomy Maximising consumer choices for
life saving breast cancer treatment;
freedom from misleading influences
on consumer screening participation
Maximising consumer
choices for life saving breast
cancer treatment
Facilitating informed consumer decision
making about screening, freedom from
external (positive or negative) influences
on decision makinga
Transparency n/a Telling consumers what
might happen when
participating in screeninga
Telling consumers what might happen
when participating in screening
Professional
responsibility
Providing guidance on healthy
living to the population
Providing guidance on
healthy living to the
population
Providing full information to the
population about healthy living
Respect for public
preferences regarding
decision-making
responsibility
Consumers want to be told what
to do
Consumers want to be told
what to do; consumers want
full information
Consumers want full information
avalues that were prioritised for this particular communication approach
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study, however, illustrates the complexity of using such
an apparently simple framework in a particular, practical
context, by showing that the prioritisation and interpret-
ation of the same values amongst influential experts is
not consistent. Significantly, our results indicate that the
same bare list of values could be used by different
experts to potentially justify each of three very different
communication approaches. In order to use values and
principles to assist and steer policy, rather than “rubber
stamp” existing plans, greater discussion of the meanings
of values is required, situated in a concrete context (in
this case, breast screening).
To support experts and others who are involved in
shaping polices on communication with consumers about
breast screening, we suggest the following questions as a
structure to guide decision-making:
What values should drive this communication?
A wide range of values relevant to public health should
be considered before deciding which one/s should be
prioritised in this particular context. Those involved in
discussions might start with the values that have been
discussed in this paper: delivering benefits, avoiding
harms, delivering more benefits than harms, respect for
autonomy, transparency, professional responsibility and
respect for public preferences regarding decision-making
responsibility. The ethics literature suggests other values
that were not raised by these experts, including distribu-
tive justice, procedural justice and trust [67–70]. Decid-
ing which of these values to prioritise in any given
context will not always be easy [68]. For the purposes of
communication with consumers about breast screening,
there is likely to be strong debate around the relative
importance of two potentially conflicted values: deliver-
ing more benefits than harms, and respecting autonomy.
Central tasks here are to agree which values are import-
ant and develop a shared understanding of what these
values mean [52]. Existing public health ethics frame-
works provide some guidance [67–70].
How will selected value/s be prioritised?
In order to address this question it may be useful to
debate different conceptions of values and consider what
communication aims would correspond with each. Note
that the priority value/s are decided first, and these will
help to identify and guide the stated aims of the commu-
nication. Imagine, for example, the main value is to de-
liver more benefits than harms. This raises the question
of whether it should be experts or consumers who de-
fine which benefits and harms matter and how they are
weighed. If the conclusion is that experts should decide,
then the aim of communication may be to persuade
consumers to act in line with expert assessment. If, in
contrast, the decision is that consumers should make
their own decisions about which benefits and harms
matter and how they should be weighed, then the aim of
screening communication would be to encourage con-
sumer understanding and choice.
What communication strategy corresponds to these
selected aims?
It will be necessary at this point to build on answers to
the questions above. For example, if it is decided that
the main value is to deliver more benefits than harms,
and that this is best achieved by persuading consumers
to act in accordance with expert opinion, then a “Be
Screened” approach would be recommended (or a “Be
Screened and here’s why” approach, if transparency was
also selected as an important value). However if it is
decided that delivering more benefits than harms is best
achieved by encouraging consumer understanding and
choice then the “Screening is available, please consider
whether its right for you” strategy will be selected for
communicating about breast screening.
Our study’s strengths include its detail and depth of
coverage through interviews with a broad range of experts
from different fields and locations across the country.
We must consider that the study may be limited due
to its geographic focus on Australian experts. It is likely,
however, that our findings will have broader application
beyond this country since the nature and detail of the
breast screening program in Australia is similar to those
throughout much of UK and Europe, and the values and
principles discussed by the experts are well recognised
worldwide. It is also possible that our findings are lim-
ited by the participating sample – that is, we must con-
sider the question of whether or not the experts who
were asked but did not participate held different views
to those who did participate. Since we specifically sought
to include participants from a range of professional roles
and attitudes to screening, and since we continued sam-
pling until we reached thematic saturation, we are
confident that our study has mapped a sufficiently wide
range of opinions and values [57].
Conclusions
This study provides the first empirical explanation of
why well-informed experts take such different views on
communication with consumers about breast screening.
Experts do not necessarily have the same values prior-
ities in mind, and even if they do, they do not necessarily
agree on what actions would be in line with that particu-
lar value. Thus there are layers of difficulties in imple-
menting recommended public health ethics frameworks
as guidance for public health policy. We advocate for
greater research into values thinking amongst public
health policy makers, and would encourage explicit and
ongoing discussions about what values mean and which
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ones are important and why. In the meantime we pro-
vide step-by-step guidance as to how to use values in
policy making within the context of breast screening in
order to develop ethically robust communication strat-
egies for consumers.
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